170 related articles for article (PubMed ID: 26082438)
21. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis.
Ovbiagele B; Saver JL; Lynn MJ; Chimowitz M;
Neurology; 2006 May; 66(9):1344-9. PubMed ID: 16682665
[TBL] [Abstract][Full Text] [Related]
22. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
[TBL] [Abstract][Full Text] [Related]
23. Metabolic syndrome affects midterm outcome after coronary artery bypass grafting.
Angeloni E; Melina G; Benedetto U; Refice S; Capuano F; Roscitano A; Comito C; Sinatra R
Ann Thorac Surg; 2012 Feb; 93(2):537-44. PubMed ID: 22197615
[TBL] [Abstract][Full Text] [Related]
24. High serum uric acid levels increase the risk of metabolic syndrome in elderly women: The PRO.V.A study.
Zurlo A; Veronese N; Giantin V; Maselli M; Zambon S; Maggi S; Musacchio E; Toffanello ED; Sartori L; Perissinotto E; Crepaldi G; Manzato E; Sergi G
Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):27-35. PubMed ID: 26643208
[TBL] [Abstract][Full Text] [Related]
25. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
26. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome: Results from Fangchenggang Area Male Health and Examination Survey in China.
Chen D; Zhang H; Gao Y; Lu Z; Yao Z; Jiang Y; Lin X; Wu C; Yang X; Tan A; Mo Z
Clin Chim Acta; 2015 Jun; 446():226-30. PubMed ID: 25913163
[TBL] [Abstract][Full Text] [Related]
27. Impact of metabolic syndrome on future cardiovascular events in patients with first acute myocardial infarction.
Selcuk H; Temizhan A; Selcuk MT; Sen T; Maden O; Tekeli S; Sasmaz A
Coron Artery Dis; 2009 Sep; 20(6):370-5. PubMed ID: 19609207
[TBL] [Abstract][Full Text] [Related]
28. CALy Prognostic Score (CEA, ALP, Lymphocyte Count) as a predictor of survival after hepatectomy for liver-only colorectal metastases.
Neofytou K; Giakoustidis A; Mudan S
J BUON; 2015; 20(3):746-55. PubMed ID: 26214626
[TBL] [Abstract][Full Text] [Related]
29. Effect of metabolic syndrome and its components on recurrence and survival in early-stage non-small cell lung cancer.
Wen YS; Zhang XW; Qin RQ; Zhang LJ
Med Oncol; 2015 Jan; 32(1):423. PubMed ID: 25476482
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Cao X; Chen YZ; Luo RZ; Zhang L; Zhang SL; Zeng J; Jiang YC; Han YJ; Wen ZS
Oncotarget; 2015 May; 6(13):11704-13. PubMed ID: 25868976
[TBL] [Abstract][Full Text] [Related]
31. Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients.
Andreoni B; Chiappa A; Bertani E; Bellomi M; Orecchia R; Zampino M; Fazio N; Venturino M; Orsi F; Sonzogni A; Pace U; Monfardini L
World J Surg Oncol; 2007 Jul; 5():73. PubMed ID: 17610720
[TBL] [Abstract][Full Text] [Related]
32. Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations.
Solymoss BC; Bourassa MG; Marcil M; Levesque S; Varga S; Campeau L
Coron Artery Dis; 2009 Jan; 20(1):1-8. PubMed ID: 19050599
[TBL] [Abstract][Full Text] [Related]
33. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients.
Yang Y; Mauldin PD; Ebeling M; Hulsey TC; Liu B; Thomas MB; Camp ER; Esnaola NF
Cancer; 2013 Apr; 119(8):1512-20. PubMed ID: 23280333
[TBL] [Abstract][Full Text] [Related]
34. Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis.
Udell JA; Steg PG; Scirica BM; Eagle KA; Ohman EM; Goto S; Alsheikh-Ali AA; Porath A; Corbalan R; Umez-Eronini AA; Hoffman EB; Wilson PW; Bhatt DL;
Eur J Prev Cardiol; 2014 Dec; 21(12):1531-40. PubMed ID: 23918840
[TBL] [Abstract][Full Text] [Related]
35. CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer.
Sun H; Wang C; Hao M; Sun R; Wang Y; Liu T; Cong X; Liu Y
Hum Pathol; 2016 Apr; 50():101-8. PubMed ID: 26997443
[TBL] [Abstract][Full Text] [Related]
36. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Ruiz-Millo O; Albert-Mari A; Sendra-Garcia A; Jimenez-Torres NV
J Oncol Pharm Pract; 2014 Oct; 20(5):341-50. PubMed ID: 24177355
[TBL] [Abstract][Full Text] [Related]
37. The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer.
Sclafani F; Incarbone M; Rimassa L; Personeni N; Giordano L; Alloisio M; Santoro A
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):97-103. PubMed ID: 22939863
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer.
Tang K; Wang C; Chen Z; Xu H; Ye Z
Int J Clin Exp Pathol; 2015; 8(5):4999-5007. PubMed ID: 26191193
[TBL] [Abstract][Full Text] [Related]
39. Colorectal liver metastases: hepatic pedicle clamping during hepatectomy reduces the incidence of tumor recurrence in selected patients. Case-matched analysis.
De Carlis L; Di Sandro S; Giacomoni A; Mihaylov P; Lauterio A; Mangoni I; Cusumano C; Poli C; Tripepi M; Bencardino K
Eur J Surg Oncol; 2013 Jul; 39(7):726-33. PubMed ID: 23601983
[TBL] [Abstract][Full Text] [Related]
40. Disease-Free Survival after Simultaneous or Delayed Resection of Synchronous Colorectal Liver Metastasis and Primary Cancer.
Bigourdan JM; Faber B; Rayar M; Chirpaz E; Boucher E; Boudjema K
Hepatogastroenterology; 2014 Jun; 61(132):1074-81. PubMed ID: 26158168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
